Offer - Urjas Oil for just ₹ 1 X
Gevast is an allopathic medicine The correct dosage of Gevast depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Gevast is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
Is the use of Gevast safe for pregnant women?
Gevast should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Gevast safe during breastfeeding?
Gevast may have very limited harmful effects for breastfeeding women.
What is the effect of Gevast on the Kidneys?
There can be some harmful effects on your kidneys after taking Gevast. If you witness any side effects, discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Gevast on the Liver?
The liver can be affected by Gevast. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Gevast only after medical advice.
What is the effect of Gevast on the Heart?
Very few cases of side effects of Gevast on the heart have been reported.
Gevast should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Gevast unless your doctor advises you to do so -
Is this Gevast habit forming or addictive?
No, there is no any evidence that Gevast is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can comfortably use machinery or drive after taking Gevast since it will not make you feel sleepy.
Is it safe?
Gevast is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Gevast cannot treat any kind of mental disorder.
Interaction between Food and Gevast
When consumed with certain foods, Gevast may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Gevast
Consumption of alcohol and Gevast together may have severe effects on your health.
Use Gevast as advised by your doctor. Do not discontinue the drug suddenly or use it longer than prescribed by your doctor.
No, Gevast does not cause diabetes. It has not been reported to cause diabetes. However, Gevast might increase your blood sugar levels slightly. So, if you have diabetes keep a check on your blood sugar levels and in case of a sudden spike inform your doctor and take medicines accordingly.
No, use of Gevast does not cause memory loss in the patients who are taking it. It has not been reported to cause memory loss.
Yes, Gevast is safe to use, if taken in a prescribed amount for a specified time as advised by the doctor. However, few side effects are observed at regular doses such as confusion, diarrhea, joint pain, and muscle pain. Do not hesitate to inform your doctor if you are facing any of the above.
No, Gevast is a prescription drug so do not take it without consulting a doctor. It can be harmful for the patient to take this medicine without a doctor's recommendation because it can cause very unpleasant side effects. Hence, patient should seek doctors advice before taking this medication by himself or herself.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650